NCT03254004

Postoperative Pembrolizumab for the Patients Who Have Solid Predominant or Micropapillary Lung Adenocarcinoma With Pathologic Stage I and Primary Tumor Than 4 cm

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 70 (estimated)
• Sponsor: Samsung Medical Center · Academic / Other
• Sex: All
• Age: 20 Years
• Healthy volunteers: Not accepted

Summary

A single center, open-label, single arm study in patients who have solid or micropapillary adenocarcinoma with pathologic stage I and primary tumor no more than 4 cm. Pembrolizumab 200 mg every 3 weeks

Detailed description

This is a single center, open-label, single arm study in patients who have solid or micropapillary adenocarcinoma with pathologic stage I and primary tumor no more than 4 cm. Patients will be treated with pembrolizumab 200 mg every 3 weeks till 1 year or disease recurrence or intolerable toxicity.

Conditions

• Lung Adenocarcinoma, Stage I

Interventions

Type	Name	Description
DRUG	Pembrolizumab	pembrolizumab 200 mg every 3 weeks till 1 year or disease recurrence or intolerable toxicity.

Timeline

• Start date: 2018-10-08
• Primary completion: 2021-03-30
• Completion: 2021-11-30
• First posted: 2017-08-18
• Last updated: 2020-12-14

Locations

1 site across 1 country: South Korea